Intro: Biomarkers in RA

Slides:

Advertisements

Similar presentations

Consultant Rheumatologist

Advertisements

Upfront Combination Therapy vs Step-Up Approach for PAH:

nAMD: Choosing the Best Treatment for your Patient

Highlights From the 2017 Annual European MS Meeting

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

A Paradigm Shift in PAH.

Effective Management of Psoriatic Arthritis: Tailoring Treatments

Objective Assessment of RA: Expanding the Horizons

Diagnosing Rheumatoid Arthritis Early

UNDERSTANDING RISK STRATIFICATION IN PAH:

Progression After Cancer Immunotherapy in Advanced NSCLC

Progressive Fibrosing Interstitial Lung Diseases – Addressing the Challenges Concept of Progressive Fibrosing ILDs With Examples.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Advances in Dry Eye.

Clinical Cases in Glaucoma Treatment

All About PAH:.

nAMD: Switching Therapies - what you need to know

Chronic Idiopathic Urticaria

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Decision-making in the eRA of Treating to Target

Disease Activity Assessment Across the RA Continuum

Precision Management of RA and Comorbidities

Are We Closer to Personalized Medicine in MS?

Case Collection in RA: Highlights of an Interactive Workshop

Is RA Treatment Addressing the Real Needs of Patients?

Antithrombotic Protection in CAD and HF

Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Evaluating Next-Generation BTK Inhibitors

2013 World Symposium on PH CTEPH Diagnosisa 2013 World Symposium on PH (cont) CTEPH Treatmenta.

Oral Anticoagulation in AF

Evolving Treatment Landscape for PsA

Debating the Issues in Rheumatoid Arthritis with the Experts: Early Treatment and Targets.

Personalized Therapy in Relapsed or Refractory CLL

Translating the Latest and Greatest Advances in PAH Into Clinical Practice.

Introduction. Clinical Scenario: Encouraging Adherence in Patients with Schizophrenia.

Managing Polycythemia Vera in the Community Setting

Improving Outcomes in Psoriatic Arthritis

Overcoming Clinical Inertia

CDK4/6 Biomarkers: Issues and Opportunities

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

The Road to Quality Improvement in HER2-Positive Breast Cancer

Advancing Patient Care in RA

Factor Xa Inhibitors in PAD

nAMD: Choosing the Best Treatment for your Patient

PAH-Related Morbidity as a Predictor of Mortality

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

New ELN Recommendations

Patient Questions and Expert Answers in Psoriasis:

Severe Asthma and Comorbidities

Are We Making Progress in the Management of Huntington Disease?

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Disease Burden of VTE Phases of VTE Treatment.

Individualizing Therapy for RA: Are We There Yet?

Clinical Challenges in the Patient With Relapsed Multiple Myeloma

MS, Age, and Immune Function

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice.

Pulmonary Arterial Hypertension and Hospitalizations

Updates in Progressive MS

New Options for the Treatment of Hepatocellular Carcinoma

Balancing the Risks and Benefits of Multidrug Regimens in the Clinical Management of Nontuberculous Mycobacterial Lung Disease.

My PAH Patient.

Foundations of Asthma.

Shared Decision Making in MS

ACPA and RF titres in patients with early RA treated with abatacept+MTX compared with MTX alone. ACPA and RF titres in patients with early RA treated with.

Motor Fluctuations in PD

Psoriatic Arthritis.

Presentation transcript:

Identifying Patients With Early, Progressive RA: Where Do We Stand Today?

Intro: Biomarkers in RA

The Importance of Biomarkers: 2010 ACR/EULAR RA Classification Criteria

ACPA vs RF: Specificity/Sensitivity

Case Discussion: Patient With Early RA

Patient Evaluation

Citrullination

Anti-PAD4 Associations: Disease Duration and Anti-CCP

Genetic and Environmental Contributions to RA Pathogenesis

Treatment Plan

ACPA Signals Worsened Prognosis

Additional Poor Prognostic Indicators in RA

PAD4 and Radiographic Damage

Treat Presymptomatic ACPA-Positive Patients?

Test First-Degree Relatives?

Patient Follow-Up, 3 Months

Development of RA: Genetic Risk

RA, ACPAs, and Smoking

Impact of Baseline ACPA Level on Treatment Efficacy: AMPLE Trial

Can ACPA Status Affect Treatment Response?

Concluding Remarks

Abbreviations

Abbreviations (cont)